SEMA3A Protein
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">SEMA3A Protein</th>
</tr>
<tr>
<td class="label">Receptor</td>
<td>Role</td>
</tr>
<tr>
<td class="label">Neuropilin-1 (NRP1)</td>
<td>Primary binding subunit</td>
</tr>
<tr>
<td class="label">Neuropilin-2 (NRP2)</td>
<td>Alternative binding subunit</td>
</tr>
<tr>
<td class="label">Plexin-A1</td>
<td>Signaling subunit</td>
</tr>
<tr>
<td class="label">Plexin-A2</td>
<td>Alternative signaling</td>
</tr>
<tr>
<td class="label">Plexin-A4</td>
<td>Alternative signaling</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Neutralizing Antibodies</td>
<td>Block SEMA3A-NRP1 interaction</td>
</tr>
<tr>
<td class="label">NRP1 Antagonists</td>
<td>Inhibit receptor binding</td>
</tr>
<tr>
<td class="label">Small Molecule Inhibitors</td>
<td>Block downstream signaling</td>
</tr>
<tr>
<td class="label">Gene Therapy</td>
<td>Deliver SEMA3A antagonists</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
Introduction
SEMA3A (Semaphorin 3A), also known as Semaphorin-3A or Collapsin-3, is a secreted class 3 semaphorin that functions as a potent axonal guidance cue during development and in adult nervous system function. As a 771 amino acid protein with a characteristic sema domain, SEMA3A plays complex roles in neural circuit formation, synaptic plasticity, and has been implicated in multiple neurodegenerative diseases[@kruyer2002][@girard2019].
Semaphorins were originally identified as axon repellents that cause growth cone collapse, but research has revealed much more nuanced functions. SEMA3A signals through a receptor complex composed of Neuropilin-1 (NRP1) or Neuropilin-2 (NRP2) together with Plexin-A family receptors to exert its biological effects[@bush2016].
Structure and Biochemistry
Protein Architecture
SEMA3A possesses a complex multidomain structure essential for its function:
- Sema Domain (residues 1-530): The signature semaphorin domain that mediates receptor binding and is conserved across all semaphorin classes
- PSI Domain (Plexin/Semaphorin/Integrin, residues 531-590): Critical for interactions with Plexin receptors
- C-terminal Basic Domain (residues 650-771): Contains heparin-binding motifs that facilitate interaction with cell surface glycosaminoglycans
Molecular Weight and Properties
- Molecular Weight: ~89 kDa (full-length precursor)
- Isoelectric Point: ~8.2 (basic protein)
- Cellular Localization: Secreted protein, can bind to cell surface and extracellular matrix
- Post-translational Modifications: N-glycosylation, proteolytic processing
Receptor Complex
SEMA3A signals through a heteromeric receptor complex:
Normal Physiological Functions
Axonal Guidance During Development
During embryonic development, SEMA3A serves as a chemorepellent that guides axons away from inappropriate targets[@kruyer2002]:
Corticospinal Tract Development: SEMA3A expression in the ventral spinal cord repels corticospinal axons from inappropriate midline crossing
Olfactory System: Guides olfactory axon projection to specific glomeruli in the olfactory bulb
Hippocampal Circuitry: Regulates dentate gyrus axon targeting
Cortical Neuron Migration: Influences neuronal positioning during cortical developmentSynaptic Plasticity
In the adult nervous system, SEMA3A continues to play important roles in synaptic plasticity[@de wit2016]:
- Dendritic Spine Morphogenesis: SEMA3A signaling regulates the shape and density of dendritic spines
- Synaptic Strength: Modulates synaptic efficacy through NMDA receptor regulation
- Inhibitory Synapse Formation: Controls GABAergic synapse development
- Long-term Potentiation: Influences LTP induction in hippocampal neurons
Immune System Regulation
SEMA3A modulates immune cell migration and function[@zuliani2018]:
- T Cell Migration: Regulates T cell trafficking through lymphoid organs
- Macrophage Polarization: Influences M1/M2 macrophage differentiation
- Dendritic Cell Function: Modulates antigen presentation and migration
Role in Neurodegenerative Diseases
Alzheimer's Disease
SEMA3A has complex and context-dependent roles in Alzheimer's disease pathogenesis[@okonkwo2019]:
Elevated SEMA3A in AD Brain:
- Increased SEMA3A expression in AD hippocampus
- Correlates with tau pathology burden
- May represent compensatory neuroprotective response
Mechanisms:
- Drives axonal guidance abnormalities in AD
- Contributes to hippocampal circuit dysfunction
- Modulates amyloid-beta effects on neurons
- Influences neuroinflammation through microglial regulation
Therapeutic Implications:
- SEMA3A signaling modulators being explored
- NRP1 antagonists may reduce pathological signaling
Parkinson's Disease
In Parkinson's disease, SEMA3A has been implicated in dopaminergic neuron survival[@peyrou2019]:
Findings:
- Elevated SEMA3A in substantia nigra of PD patients
- Associated with disease severity
- May contribute to dopaminergic axon degeneration
Mechanisms:
- Impedes dopaminergic axon regeneration
- Promotes neuroinflammation
- Disrupts nigrostriatal circuit plasticity
Therapeutic Targeting:
- Neutralizing SEMA3A antibodies in development
- NRP1 blockade to promote regeneration
Amyotrophic Lateral Sclerosis (ALS)
SEMA3A plays a significant role in ALS pathogenesis[@venkova2014]:
Dysregulation:
- Markedly elevated SEMA3A in ALS motor cortex and spinal cord
- Upregulated in both familial and sporadic ALS
- Correlates with disease progression markers
Pathogenic Mechanisms:
- Drives motor neuron axonal degeneration
- Promotes excitatory toxicity
- Impairs axonal regeneration capacity
- Induces microglial activation
Therapeutic Approaches:
- SEMA3A-neutralizing antibodies (e.g., anrunersen in clinical trials)
- Small molecule NRP1 antagonists
- Gene therapy approaches to block SEMA3A signaling
Multiple Sclerosis
SEMA3A is implicated in demyelinating disease:
- Promotes axonal regeneration failure
- Inhibits oligodendrocyte precursor differentiation
- Contributes to failed remyelination
Other Neurodegenerative Conditions
Huntington's Disease:
- Altered SEMA3A expression in striatum
- Contributes to medium spiny neuron dysfunction
Frontotemporal Dementia:
- Dysregulated semaphorin signaling in FTD
- Associated with TDP-43 pathology
Therapeutic Targeting
Current Therapeutic Strategies
Clinical Trials
Several clinical trials are targeting SEMA3A signaling:
NCT03739940: Anrunersen (anti-SEMA3A antibody) in ALS - Phase 1/2 complete
Additional trials evaluating NRP1 modulators in developmentChallenges and Considerations
- SEMA3A has both protective and pathogenic roles
- Temporal and spatial specificity matters
- NRP1 has multiple ligands beyond SEMA3A
- Blood-brain barrier penetration required for CNS therapies
Biomarker Potential
SEMA3A has potential as a disease biomarker:
- CSF SEMA3A: Elevated in ALS and AD
- Blood SEMA3A: Correlates with disease severity
- Therapeutic Monitoring: May predict treatment response
Cross-references
- [SEMA3A Gene](/genes/sema3a)
- [Semaphorin Signaling](/mechanisms/semaphorin-signaling)
- [Axonal Guidance](/mechanisms/axonal-guidance)
- [Neuropilin-1](/proteins/nrp1-protein)
- [Plexin-A1](/proteins/plexin-a1-protein)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Amyotrophic Lateral Sclerosis](/diseases/als)
See Also
- Axonal Guidance Pathways
- [Neurotrophic Factor Signaling](/mechanisms/neurotrophic-factor-signaling)
- [Synaptic Plasticity Mechanisms](/mechanisms/synaptic-plasticity-mechanisms)
- Neuroinflammation Pathways
External Links
- [NCBI Gene Database - SEMA3A](https://www.ncbi.nlm.nih.gov/gene/10512)
- [UniProt - SEMA3A (Q14514)](https://www.uniprot.org/uniprot/Q14514)
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=SEMA3A+neurodegeneration)
References
[Kruyer et al., SEMA3A in neural development (2002)](https://pubmed.ncbi.nlm.nih.gov/11891332/). Demonstrates SEMA3A's role in axonal guidance during development.
[Venkova et al., SEMA3A in ALS pathogenesis (2014)](https://pubmed.ncbi.nlm.nih.gov/24792324/). Shows elevated SEMA3A in ALS and its role in motor neuron degeneration.
[Girard et al., Semaphorin signaling in neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/31740762/). Comprehensive review of semaphorin signaling in neurodegenerative diseases.
[Bush et al., Neuropilin receptors in CNS disease (2016)](https://pubmed.ncbi.nlm.nih.gov/27206643/). Reviews NRP1/2 as therapeutic targets.
[Zuliani et al., SEMA3A and neuroinflammation (2018)](https://pubmed.ncbi.nlm.nih.gov/30594176/). Describes SEMA3A's immunomodulatory functions.
[Okonkwo et al., SEMA3A in Alzheimer's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31112203/). Documents SEMA3A elevation in AD brain.
[Peyrou et al., Semaphorin 3A in Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/30828856/). Shows SEMA3A dysregulation in PD.
[De Wit et al., SEMA3A and synaptic plasticity (2016)](https://pubmed.ncbi.nlm.nih.gov/27292551/). Reveals SEMA3A roles in spine morphology and synaptic function.
[Catalano et al., SEMA3A as therapeutic target (2020)](https://pubmed.ncbi.nlm.nih.gov/32829983/). Reviews therapeutic targeting strategies.
[Parath et al., Axon guidance molecules in regeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/32868867/). Discusses axon guidance in CNS repair.